ALXN1720 for Myasthenia Gravis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Myasthenia GravisALXN1720 - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug, ALXN1720, for the treatment of generalized myasthenia gravis (gMG) in adults. gMG is a disease where the body's immune system attacks healthy cells, causing muscle weakness. The new drug is designed to stop the immune system from attacking healthy cells.

Eligible Conditions
  • Myasthenia Gravis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Baseline, Week 26

Week 26
Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26
Percentage of Responders based on Reduction of the QMG Total Score at Week 26
Baseline, Week 26
Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

ALXN1720
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

254 Total Participants · 2 Treatment Groups

Primary Treatment: ALXN1720 · Has Placebo Group · Phase 3

ALXN1720
CombinationProduct
Experimental Group · 1 Intervention: ALXN1720 · Intervention Types: CombinationProduct
Placebo
CombinationProduct
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week 26

Who is running the clinical trial?

Alexion PharmaceuticalsLead Sponsor
229 Previous Clinical Trials
38,224 Total Patients Enrolled
9 Trials studying Myasthenia Gravis
1,024 Patients Enrolled for Myasthenia Gravis

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Ontario100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
0100.0%